Expanded access refers to the use of an investigational drug, under certain circumstances, to treat patients with a serious disease or condition who cannot participate in a controlled clinical trial.
Radium-223 chloride is the investigational drug developed for patients diagnosed with castration-resistant prostate cancer (CRPC)/hormone-refractory prostate cancer (HRPC) with symptomatic bone metastases.
Radium-223 chloride will be made available to patients through qualified clinical sites participating in this program, the company said.
Read about this and other breaking prostate cancer news from the 2012 GU Cancers Symposium
[ PRESS RELEASE ]
